PIK3CA and prostate cancer: In conclusion, in the present study, we analyzed exclusively 79 consecutive patients of Jordanian origin with prostate cancer mainly at advanced stages and we reported TP53 mutations in 11.9 % of the patients and absence of SPOP and PIK3CA mutations in the study population.